+86-571-85081802     info@multin.cn
Clobetasol Propionate CAS 25122-46-7 Treat skin diseases with Fast Delivery
Home » Products » Pharmaceutical Intermediate » Clobetasol Propionate CAS 25122-46-7 Treat skin diseases with Fast Delivery

Product Category

Contact Us

 Tel: +86-571-85081802
  Phone: +86-13655719091
 E-mail: info@multin.cn
  Add: Room 321,lingjun Mansion South,the 10th Chaowang Road,xiacheng District,hangzhou City,zhejiang Province China

Clobetasol Propionate CAS 25122-46-7 Treat skin diseases with Fast Delivery

Share to:
sharethis sharing button
Hot Selling Pharmaceutical Raw Material Powder 99% Clobetasol Propionate 25122-46-7, find complete details about Hot Selling Pharmaceutical Raw Material Powder 99% Clobetasol Propionate 25122-46-7, Clobetasol Propionate, Clobetasol Propionate powder, Clobetasol Propionate price - Multinpharma
  • 25122-46-7

  • MT

  • 25122-46-7

  • 25122-46-7

Availability:

tianeptine 2

 
Product Name
Clobetasol Propionate powder
Appearance
White lyophilized powder
Assay
99%min 
Test
HPLC 
Certificate
ISO 9001
CAS
25122-46-7
MF C25H32ClFO5
Storage Temperature
Cool Dry Place

Application:
 
Adrenocorticotropic hormone drugs, anti-inflammatory, anti-allergic and anti-drug more effective than prednisone, and promoting the removal of potassium sodium retention is very light, intramuscular or intravenous pituitary - adrenal strong inhibition:

1. Anti-inflammatory effects: The product can reduce and prevent tissue response to inflammation, thereby reducing inflammation performance. Hormone suppression of inflammatory cells, including leukocytes and macrophages accumulation in sites of inflammation and inhibition of phagocytosis, lysosomal enzyme release and synthesis and release of inflammatory chemical mediators. Can reduce and prevent tissue response to inflammation, thereby reducing inflammation performance. 

2. Immunosuppressive effect: preventing or inhibiting cell-mediated immune response, delayed hypersensitivity reactions, reducing T lymphocytes, monocytes, eosinophils, reducing immunoglobulin binding to cell surface receptors and inhibition of the synthesis and release of interleukin, thus reducing the T lymphocyte transformation of lymphoblastoid cells, and reduce the extension of the primary immune response. Can reduce immune complexes through the basement membrane, and can reduce the concentration of ingredients complement and immunoglobulins.

13457







Previous: 
Next: 

Related Products

OUR PRODUCTS

HOT LINKS

Copyright  2020 ZHEJIANG MULTINPHARMA CO.,LTD All Rights Reserved  浙ICP备17013806号-1  |  Technology by www.leadong.com